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Objectives:	To	compare	effects	of	norepinephrine	and	angiotensin	
II	 in	experimental	sepsis	on	hemodynamics,	organ	function,	and	
mitochondrial	respiration.
Design:	Randomized,	controlled,	study.
Setting:	University	experimental	laboratory.
Subjects:	Twenty-eight	anesthetized,	mechanically	ventilated	pigs.
Interventions:	Sixteen	pigs	were	randomized	to	receive	after	12	
hours	of	fecal	peritonitis	fluid	resuscitation	and	either	norepineph-
rine	(group	NE;	n	=	8)	or	angiotensin	 II	 (group	AT-II;	n	=	8)	 for	
48	hours.	A	separate	group	(n	=	8),	treated	with	enalapril	 for	1	
week	before	peritonitis	 and	until	 study	end,	 received	fluids	and	
norepinephrine	(group	E).	The	blood	pressure	dose-response	to	
angiotensin	II	was	evaluated	in	additional	four	nonseptic	pigs.
Measurements and Main Results:	 Blood	 pressure	 	target	
(75–85	mm	Hg)	was	reached	in	both	NE	and	AT-II,	and		cardiac	out-
put	increased	similarly	(NE:	from	64	mL/kg/min	[60–79	mL/kg/min]	
to	139	mL/kg/min	[126–157	mL/kg/min];	AT-II	from	79	mL/kg/min	
[65–86	mL/kg/min]	 to	 145	mL/kg/min	 [126–147	mL/kg/min];	
median,	 interquartile	 range).	 Renal	 plasma	 flow,	 prevalence	 of	
acute	 kidney	 injury,	 inflammation	 and	 	coagulation	 patterns,	 and	
mitochondrial	 respiration	 did	 not	 differ	 between	 NE	 and	 AT-II.	
In	 group	 E,	 blood	 pressure	 targets	 were	 not	 achieved	 (mean	
arterial	pressure	at	 study	end:	NE:	81	mm	Hg	 [76–85	mm	Hg];	
AT-II:	80	mm	Hg	[77–84	mm	Hg];	E:	53	mm	Hg	[49–66	mm	Hg],	 
p	=	0.002,	compared	to	NE),	whereas	skeletal	muscle	adenosine	
triphosphate	concentrations	were	increased.	During	resuscitation	
one	animal	died	in	groups	AT-II	and	E.
Conclusions:	Angiotensin	II	reversed	sepsis-induced	hypotension	
with	systemic	and	regional	hemodynamic	effects	similar	to	those	
of	 norepinephrine.	 Inhibition	 of	 angiotensin-converting	 enzyme	
before	sepsis	worsened	 the	hypotension	but	enhanced	skeletal	
muscle	adenosine	 triphosphate.	Modifying	 the	 renin-angiotensin	
system	 in	 sepsis	 should	 be	 further	 evaluated.	 (Crit Care Med 
2014;	42:e550–e559)
Key Words:	 angiotensin	 II;	 enalapril;	 mitochondrial	 respiration;	
multiple	organ	failure;	norepinephrine;	septic	shock
Norepinephrine is the standard vasopressor to treat septic shock (1, 2). High doses of catecholamines may contribute to organ dysfunction and mortality in 
sepsis (3, 4). Vasopressin has been proposed as an additional 
treatment of septic hypotension in order to reduce the need for 
catecholamine vasopressors and their potential adverse effects. 
In a large multicenter trial, vasopressin failed to reduce mor-
tality in septic shock (5). Angiotensin II, a strong physiologic 
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vasoconstrictor, might be able to reverse the vasoplegia associ-
ated with septic shock. Some reports of its clinical use to treat 
severe hypotension in septic shock have been published (6–8). 
In short-term experimental sepsis, angiotensin II preserved 
renal function and bioenergetics despite reduction of renal 
blood flow (9, 10). Angiotensin II may modify tissue energy 
metabolism either directly or via its effects on tissue perfusion. 
The effect of angiotensin II on tissue energy metabolism of 
extrarenal tissues in sepsis is not known. Based on these obser-
vations, we hypothesized that angiotensin II can be used to sta-
bilize hemodynamics in experimental sepsis without adverse 
effects on renal function or mitochondrial respiration. To test 
this hypothesis, we compared the effects of angiotensin II and 
norepinephrine on systemic and regional hemodynamics, 
renal function, and renal, hepatic, and cardiac mitochondrial 
respiration in a clinically relevant porcine abdominal sepsis 
model. In order to assess the role of endogenous angiotensin, 
a separate group with inhibition of angiotensin-converting 
enzyme prior and during sepsis was studied.
MATERIALS AND METHODS
This study was performed in accordance with the National 
Institutes of Health guidelines for the care and use of experi-
mental animals and with the approval of the Animal Care 
Committee of the Canton of Bern, Switzerland.
Twenty domestic male pigs (weight: 41 kg [40–43 kg]; median, 
interquartile range [IQR]) were randomized to fecal peritonitis 
(n = 16) or controls (n = 4). Peritonitis animals were further ran-
domized to fluid resuscitation and norepinephrine (maximum 
dose: 5,000 μg/hr) or angiotensin II infusion (maximum dose: 
1,000 ng/kg/min) (n = 8, each) to maintain a mean arterial blood 
pressure of 75–85 mm Hg. This randomization occurred only at 
the end of the observation period, just before sepsis treatment 
started (Fig. 1). Block randomization with sealed envelopes 
was used (2 × 8 envelopes). In the four controls, angiotensin II 
(maximum dose, 23–27 ng/kg/min) was infused 18 hours after 
instrumentation to evaluate the dose effect in nonseptic ani-
mals (described in the supplemental data, Supplemental Digital 
Content 1, http://links.lww.com/CCM/A965).
In a separate group (n = 8; weight: 39 kg [38–40 kg]), the 
angiotensin-converting enzyme was inhibited with enalapril 
20 mg/d orally 1 week before the experiment. To sustain the 
inhibition of angiotensin-converting enzyme, a low dose of 
enalapril (0.02 mg/kg/hr, reduced if hypotensive despite resus-
citation) was infused during treatment of septic shock with 
fluids and norepinephrine (maximum dose: 5,000 μg/hr). 
A septic control group without treatment was not included 
because such a group was part of a previous study using the 
same experimental model (11).
Surgical Preparation
A pulmonary artery catheter was inserted via the right jugu-
lar vein, and femoral veins were catheterized. A catheter was 
placed into the right kidney vein via right femoral vein under 
fluoroscopy. An arterial catheter for blood pressure measure-
ment and blood sampling was placed into the right carotid 
artery. A 4-mm ultrasound Doppler flow probe (Transonic 
Systems, Ithaca, NY) was placed around the left carotid and 
femoral arteries. A cystostomy for urine drainage was per-
formed. After preparation, the abdominal incision was closed. 
Ringer’s lactate (RL) was infused at 3 mL/kg/hr during surgery.
Study Protocol, Monitoring, and Blood Sampling
Surgical preparation was followed by 6 hours of stabilization. 
RL for hydration and glucose 50% (G50%) to keep blood 
glucose at 3.5–5.0 mmol/L were infused (total 1.5 mL/kg/hr). 
Then, baseline measurements were performed, and fecal peri-
tonitis was induced by peritoneal instillation of 2 g/kg body 
weight of autologous feces dissolved in 200 mL of warmed glu-
cose 5% solution (Fig. 1).
After 12 hours of peritonitis, 48 hours of protocolized 
resuscitation was started (resuscitation period) (Fig. S1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
A965). Resuscitation was conducted by trained intensivists as 
published before (11, 12). The volume status was evaluated 
clinically every hour. If signs of hypovolemia became evident, 
alternating boluses of 150 mL RL and 6% hydroxyethyl starch 
(130/0.4) were given. If mean arterial blood pressure was lower 
than 75 mm Hg, vasopressors (norepinephrine or angioten-
sin II) were given. For further details, see supplemental data 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
A965). Following 48 hours of protocolized resuscitation, the 
animals were deeply sedated and euthanized with an over-
dose of potassium chloride. 
Monitoring and blood sampling 
are described in the supplemen-
tal data (Supplemental Digital 
Content 1, http://links.lww.
com/CCM/A965).
Estimation of Renal Blood 
Flow and Function
Renal blood flow was estimated 
using primed, continuous 
infusion of para-aminohippu-
rate (PAH; Aminohippurate 
sodium; Merck, Whitehouse 
Figure 1. Study design and basal fluid infusion rates. BL = baseline, PI = peritonitis induction, EOP = end of 
observation period (before starting resuscitation), End = end of the experiment (at 48 hr of resuscitation or 
before death if earlier). *Administration of enalapril for 7 days before the study for enalapril group, A: surgery 
period (1–2 hr), B: stabilization period (6 hr), black triangles: thromboelastography analysis, black star: first 
dose of IV antibiotic (piperacillin/tazobactam, 2.25 g, 8-hourly), black circle: samples from the right quadriceps 
muscle to assess skeletal muscle ATP content, black square: tissue samples from the liver, heart, and kidney for 
mitochondrial function analysis at the end of the experiment (66 hr or before death, if earlier).
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Station, NJ). Acute kidney injury (AKI) was defined accord-
ing to the Acute Kidney Injury Network criteria (11, 13). For 
details, see supplemental data (Supplemental Digital Content 
1, http://links.lww.com/CCM/A965).
Mitochondrial Function Analysis and Skeletal  
Muscle Adenosine Triphosphate Content
Tissue samples were taken from the kidney, liver, and heart 
sequentially and immediately put on ice at the end of the 
experiment, before euthanasia. In animals which died earlier, 
the final samples were taken when the animals were still alive 
and receiving the maximal vasopressor dose and when mean 
arterial blood pressure approached 30 mm Hg. Mitochondria 
of the various tissues were analyzed as previously described 
(11, 14, 15). For details, see supplemental data (Supplemental 
Digital Content 1, http://links.lww.com/CCM/A965).
Complex I-, II-, and IV-dependent respiration rates were 
measured using high-resolution respirometry (Oxygraph-2k; 
Oroboros Instruments, Innsbruck, Austria). Further details 
and measurement of muscle adenosine triphosphate (ATP) 
content are indicated in supplemental data (Supplemental 
Digital Content 1, http://links.lww.com/CCM/A965).
Statistical Analysis
The primary and main analysis was performed between the 
two randomized groups AT-II (angiotensin II) and NE (nor-
epinephrine). In addition, post hoc comparisons were made 
between (nonrandomized) groups E (enalapril + norepi-
nephrine) and NE. Since randomization between AT-II and 
NE occurred only at the end of the observation period (EOP; 
before sepsis treatment started), baseline measurements were 
not included in the within-group analysis in order to avoid 
more than one prerandomization measurement. Mann-Whit-
ney U test or Wilcoxon signed rank test and Friedman test were 
used for between- and within-group comparisons, respec-
tively, and Fisher exact test for categorical data. The effect of 
untreated peritonitis was assessed in the whole cohort (i.e., all 
the animals subsequently randomized) by comparing the base-
line with the EOP in the pooled NE and AT-II groups. To com-
pare the effects of peritonitis between NE/AT-II groups and 
enalapril animals, the differences between EOP and baseline 
were compared using Mann-Whitney U test. Statistical analy-
ses were performed using IBM SPSS Statistics version 20.0 for 
Windows (SPSS Inc., Armonk, NY).
RESULTS
Hemodynamic Response to Angiotensin in  
Healthy Controls
In controls, the highest dose of angiotensin II (23–27 ng/kg/min) 
resulted in an increase in blood pressure from 76 mm Hg 
(74–77 mm Hg, median, range) to 131 mm Hg (96–154 mm Hg). 
Although pulmonary artery pressure increased, cardiac output 
did not change. Further details are indicated in Table S1 and 
Figure S2 (Supplemental Digital Content 1, http://links.lww.
com/CCM/A965).
Clinical Impact of Untreated Fecal Peritonitis
Twelve hours of peritonitis without treatment in groups NE 
and AT-II resulted in decreased cardiac output and renal blood 
flow and increased arterial lactate concentration. Systemic 
oxygen consumption was maintained (Table S2, Supplemen-
tal Digital Content 1, http://links.lww.com/CCM/A965). Signs 
of AKI were observed in nine of 16 animals (56%) (Table 1), 
and fractional excretion of sodium and potassium decreased 
(Table S2, Supplemental Digital Content 1, http://links.lww.
com/CCM/A965).
Norepinephrine Versus Angiotensin II
One animal in the AT-II group died 55 hours after peri-
tonitis induction, whereas all in group NE survived. Gas 
exchange (Table S3, Supplemental Digital Content 1, http://
links.lww.com/CCM/A965) and fluid requirements during 
resuscitation (Table 2) were similar in NE and AT-II groups. 
The mean arterial blood pressure goal of 75–85 mm Hg 
was reached using 0.58 μg/kg/min (0.26–1.31 μg/kg/min) 
(median [IQR]) of norepinephrine in group NE and 309 ng/
kg/min (120–582 ng/kg/min) of angiotensin II in group AT-II 
(Table 2 and Fig. 2). Individual blood pressure evolution and 
angiotensin/norepinephrine infusion rates are displayed in 
Figure S3 (Supplemental Digital Content 1, http://links.lww.
com/CCM/A965). In both groups, approximately half of the 
animals needed continuously increasing or maximal doses 
of the vasoconstrictor. Cardiac output, stroke volume, and 
mean pulmonary artery blood pressure increased comparably 
(Fig. 3).
Arterial lactate recovered to baseline values in both groups 
(Table S4, Supplemental Digital Content 1, http://links.lww.
com/CCM/A965). Systemic and renal oxygen consumption did 
not change (Table 1) (Table S4, Supplemental Digital Content 
1, http://links.lww.com/CCM/A965). Arterial PAH concen-
trations were stable after 30 minutes of infusion (Fig. S4, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
A965). PAH clearance, which had decreased during untreated 
peritonitis, increased to baseline levels in both groups during 
the resuscitation period, and signs of AKI were attenuated dur-
ing resuscitation (Table 1).
Variables reflecting inflammation, body biochemistry, and 
coagulation were similar in both groups (Table 3) (Tables S5 
and S6, Supplemental Digital Content 1, http://links.lww.com/
CCM/A965). All animals from both groups required glucose 
infusion to maintain normal blood glucose concentrations 
(Table 2).
Mitochondrial Function and Skeletal Muscle  
ATP Content
Mitochondrial respiration rates of complex I-dependent state 
4 respiration (resting state) of isolated kidney mitochondria 
were slightly lower in the angiotensin II group in compari-
son to norepinephrine group (Fig. 4), whereas heart and 
liver mitochondrial respiration did not differ between both 
groups (Figs. S5 and S6, Supplemental Digital Content 1, 
http://links.lww.com/CCM/A965). Oxygen consumption of 
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permeabilized myocardial fibers was not affected (Fig. S7, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
A965), and skeletal muscle ATP content was not different 
between groups (Fig. 5).
Effects of Angiotensin-Converting Enzyme Inhibition
Two animals in the enalapril group died during the 12-hour 
observation before resuscitation and were subsequently 
replaced. One animal died during the resuscitation period 21 
hours after peritonitis induction. At the end of the 12-hour 
observation period, group E had higher cardiac output and 
stroke volume than group NE (Fig. 3).
Fluid requirements during resuscitation in group E were similar 
to those in group NE (Table 2). Group E failed to reach the blood 
pressure targets although all animals received the maximum dose 
of norepinephrine (Figs. 2 and 3) (Fig. S3, Supplemental Digital 
Content 1, http://links.lww.com/CCM/A965).
Renal Function
Six animals in group E had signs of AKI at the end of the experi-
ment (vs two in group NE; p = 0.066) (Table 1) despite increased 
renal plasma flow (14.4 mL/kg/min [12.7–18.5 mL/kg/min] at 
EOP vs 25.6 mL/kg/min [21.8–30.7 mL/kg/min] at study end; 
p = 0.016), stable renal oxygen consumption, and recovery of 
TABLE 1. Kidney Function Tests
Variables Group Baseline
End of the  Observation 
Period Enda pb
Creatinine (mg/dL) NE 1.1 (1.0–1.2) 1.6 (1.5–2.1) 1.0 (0.9–1.3) 0.148c
AT-II 1.1 (1.1–1.2) 1.2 (1.1–1.9) 1.2 (0.9–1.3) 0.641d
E 1.1 (1.1–1.1) 1.8 (1.2–2.0) 2.2 (1.6–3.7) 0.109e
Para-aminohippurate 
clearance  
(mL/kg/min)
NE 19.3 (14.9–24.2) (6) 12.8 (10.8–21.6) (5) 25.2 (20.5–29.1) (7) 0.063c
AT-II 18.6 (13.1–20.7) 11.7 (10.7–16.0) (7) 20.0 (17.9–26.3) 0.016d
E 15.9 (13.7–20.6) 14.4 (12.7–18.5) 25.6 (21.8–30.7) (7) 0.016e
FE sodium (%) NE 0.26 (0.16–0.51) 0.05 (0.03–0.06) 0.04 (0.04–0.05) 0.719c
AT-II 0.10 (0.07–0.15) 0.04 (0.03–0.05) 0.04 (0.03–0.06) 1.000d
E 0.09 (0.06–0.11) 0.05 (0.04–0.06) 0.12 (0.05–0.22) 0.031e
FE potassium (%) NE 25.1 (18.9–27.6) 5.6 (4.2–6.0) 5.8 (3.9–6.3) 0.844c
AT-II 13.3 (11.7–16.6) 5.8 (4.6–10.3) 2.6 (2.0–4.6) 0.047d
E 17.3 (14.8–19.9) 9.8 (6.1–10.7) 11.4 (8.3–12.6) 0.148e
Kidney Vo2 (mL/min) NE 20 (16–40) (6) 18 (15–29) (4) 17 (16–21) (6) 0.875
c
AT-II 19 (15–28) (8) 20 (15–26) (7) 19 (12–25) (7) 0.578d
E 16 (15–18) (8) 21 (18–25) (8) 17 (13–39) (7) 0.938e
Kidney Vo2/Do2 NE 0.22 (0.21–0.29) (6) 0.20 (0.16–0.23) (4) 0.16 (0.14–0.17) (6) 0.250
c
AT-II 0.25 (0.22–0.27) (8) 0.21 (0.17–0.27) (7) 0.19 (0.14–0.24) (7) 0.688d
E 0.22 (0.18–0.22) (8) 0.18 (0.17–0.22) (8) 0.13 (0.09–0.26) (7) 0.469e
Acute kidney injury, n (%) NE 7 (88%) 2 (25%) 0.041f
AT-II 2 (25%) 2 (25%) 0.569g
E 5 (63%) 6 (75%) 1.000h
0.066i
NE	=	norepinephrine,	AT-II	=	angiotensin	II	group,	E	=	enalapril	+	norepinephrine	group,	FE	=	fractional	excretion.
aEnd	of	the	experiment	(at	48	hr	of	resuscitation	or	before	death	if	earlier).
bTime	effect	with	Wilcoxon	signed	rank	test	including	end	of	the	observation	period	(EOP)	and	end	of	the	experiment	(END)	for:	cNE,	dAT-II,	and	eE.
fFisher	exact	test	at	EOP	comparing	AT-II	versus	NE.
gFisher	exact	test	at	EOP	comparing	E	versus	NE.
hFisher	exact	test	at	END	comparing	AT-II	versus	NE.
iFisher	exact	test	at	END	comparing	E	versus	NE.
Values	are	medians	with	interquartile	ranges.
Due	to	technical	problems,	few	measurements	of	the	kidney	vein	had	to	be	excluded	from	analysis,	and	the	remaining	n	of	each	group	is	indicated	in	brackets.
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fractional sodium and potassium excretion during resuscita-
tion (Table 1). Further results of enalapril-pretreated animals 
can be found in the supplemental data (Supplemental Digital 
Content 1, http://links.lww.com/CCM/A965).
DISCUSSION
The main finding of the study was that exogenous angioten-
sin II reversed sepsis-induced hypotension similarly as nor-
epinephrine. Likewise, cardiac output and stroke volume 
increased to the same extent, and renal perfusion and function 
were restored in both groups.
The cardiovascular effects of exogenous angiotensin II 
appear to be modified by the underlying clinical condition 
and experimental model. In healthy volunteers, angiotensin 
II infusion decreased cardiac output and renal blood flow in 
a dose-dependent manner (16). In ovine gram-negative sep-
sis without fluid resuscitation, 2–6 hours of angiotensin II 
infusion at doses up to 600 ng/kg/min had no major effect on 
cardiac output and had either no effect on renal blood flow 
or reversed an increased flow (9, 10). The increase of cardiac 
output in our study can be explained by the combination of 
enhanced preload with fluids and restoration of vascular tone 
by angiotensin II. We suggest that the differences between 
the present and previous studies (9, 10) on cardiac output 
and renal blood flow effects of angiotensin II are most likely 
explained by fluid resuscitation. Renin and angiotensin II con-
centrations are elevated in clinical sepsis (17). AT-1 receptors 
are down-regulated in septic mice and rats and in mice after 
cytokine injection (18, 19). It is conceivable that the increasing 
TABLE 2. Administered Treatments, Fluid Output, and Balance During the Resuscitation 
Period
Variables/Study group NE AT-II E
p p
AT-II Versus NE E Versus NE
Propofol (mg/kg/hr) 5.5 (4.9–6.1) 6.0 (4.3–6.6) 5.2 (4.7–5.4) 0.878a 0.574a
Fentanyl (μg/kg/hr)b 4.1 (3.0–5.0) 4.4 (3.3–5.9) 8.2 (7.5–8.9) 0.798a < 0.001a
Midazolam (mg/kg/hr) 0.03 (0.02–0.06) 0.04 (0.02–0.07) 0.04 (0.03–0.04) 0.959a 0.572a
Glucose 50% (mL/kg/hr) 0.9 (0.6–1.2) 0.9 (0.5–1.1) 0.3 (0.2–0.4) 0.442a < 0.001a
Fluid bolus (mL/kg/hr)c 1.6 (1.2–2.0) 1.1 (0.9–1.8) 1.9 (1.7–2.8) 0.442a 0.130a
Ringer’s lactate bolus (mL/kg/hr) 1.1 (1.0–1.4) 0.9 (0.8–1.3) 1.3 (1.3–2.2) 0.442a 0.195a
Hydroxyethyl starch bolus (mL/kg/hr) 0.4 (0.2–0.6) 0.2 (0.1–0.4) 0.5 (0.4–0.6) 0.525a 0.290a
Norepinephrine
  n/n group (%) 8/8 (100%) 8/8 (100%)
  μg/kg/min 0.58 (0.26–1.31) 1.96 (1.62–2.02) 0.002a
Angiotensin II
  n/n group (%) 8/8 (100%)
  ng/kg/min 309 (120–582)
Dobutamine
  n/n group (%) 2/8 (25%) 1/8 (12.5%) 2/8 (25%)
  μg/kg/min 0.00 (0.00–0.06) 0.00 (0.00–0.00) 0.00 (0.00–0.02) 1.000d 1.000d
Total volume received (mL/kg/hr) 4.6 (4.2–5.0) 4.1 (3.9–4.8) 4.9 (4.7–5.9) 0.442a 0.161a
Urine output (mL/kg/hr) 1.0 (0.9–1.0) 1.0 (0.8–1.2) 0.6 (0.5–1.0) 0.798a 0.038a
Gastric tube output (mL/kg/hr)e 0.3 (0.2–0.6) 0.3 (0.2–0.5) 0.5 (0.1–0.7) 0.742a 0.856a
Final balance (mL/kg/hr)f 3.2 (2.7–3.8) 2.7 (2.3–3.7) 4.0 (3.4–4.9) 0.505a 0.083a
NE	=	norepinephrine	group,	AT-II	=	angiotensin	II	group,	E	=	enalapril	+	norepinephrine	group.
aMann-Whitney	U	test.
bSum	of	basic	infusion	with	additional	boli.
cSum	of	Ringer’s	lactate	(RL)	and	hydroxyethyl	starch	(HES,	6%	[130/0.4]).
dFisher	exact	test.
eCollected	during	the	entire	study	period.
fFinal	balance:	(RL	basal	infusion	+	glucose	50%	basal	infusion	+	RL	bolus	+	HES	bolus)	–	(urine	output	+	gastric	tube	output).
Values	are	medians	with	interquartile	ranges.
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needs of angiotensin II over time to maintain blood pressure in 
our and other studies (9, 10) was due to angiotensin receptor 
down-regulation.
Classically, acute renal dysfunction during sepsis has been 
attributed to reduced kidney blood flow as a result of sys-
temic vasodilation with low blood pressure in combination 
with renal vasoconstriction due to increased renal sympa-
thetic activity and angiotensin plasma concentrations (20). 
Recently, this view has been challenged by experimental evi-
dence of increased renal blood flow and renal vasodilation 
during continuous lipopolysaccharide (LPS) infusion (21). 
This may suggest that low intraglomerular perfusion pressure 
is an important contributor to sepsis-induced acute kidney 
dysfunction. Angiotensin II with its predominant effects on 
efferent renal arterioles has therefore the potential to restore 
intrarenal hemodynamics and improve kidney function (9).
The reduced mortality in patients with community-acquired 
pneumonia (22) and multiple organ failure (23) treated with 
angiotensin-converting enzyme inhibitors has been related 
to anti-inflammatory properties of angiotensin converting 
enzyme inhibitors and their ability to restore deteriorated 
autonomic function (24–26). In our study, we found that inhi-
bition of angiotensin-converting enzyme before and during 
sepsis worsened the severity of hypotension and reduced the 
response to norepinephrine. Accordingly, in this clinically rel-
evant sepsis model, the endogenous renin-angiotensin system 
appeared to be relevant for restoring hemodynamic stability 
during the first 48 hours of resuscitation. The protective effects 
of angiotensin-converting enzyme inhibition in sepsis, if any, 
are therefore unlikely to be related to hemodynamics.
Figure 2. Systemic hemodynamics. Values are medians with interquartile ranges. NE = norepinephrine group, AT-II = angiotensin II group, E = enalapril 
+ norepinephrine group, BL = baseline, EOP = end of observation period, RP = resuscitation period, MAP = mean arterial blood pressure, MPAP = mean 
pulmonary artery pressure. p: time effect with Friedman’s test including EOP, RP 12 hr, RP 24 hr, RP 36 hr, and RP 48 hr for NE (A), AT-II (B), and E (C).
Figure 3. Administered vasopressors during the 48 hr of protocolized 
resuscitation. Values indicate medians with interquartile ranges.  
NE = norepinephrine group, AT-II = angiotensin II group, E = enalapril + 
norepinephrine group.
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In our study, renal plasma flow was similar in all groups 
at the end of the experiment, but the prevalence of AKI and 
fractional excretion of sodium and potassium were higher 
in enalapril-treated animals. Similarly, in a fluid-resuscitated 
ovine model of peritonitis with norepinephrine to treat hypo-
tension, a single dose of enalapril after peritonitis induction 
resulted in increased serum creatinine levels compared with 
placebo despite similar blood pressure levels (21). This sug-
gests an important role for intraglomerular perfusion pressure 
in preventing acute renal dysfunction in sepsis.
Administration of enalapril in our study was associated 
with increased skeletal muscle ATP content and improved 
renal mitochondrial respiration efficiency. It has been shown 
that enalapril can attenuate mitochondrial dysfunction in 
aging rats (27). On the other hand, incubation of isolated 
kidney cortex mitochondria with enalapril inhibited mito-
chondrial respiration, indicating a direct effect of enalapril 
on nicotinamide adenine dinucleotide/cytochrome c oxido-
reductase (28). How the high doses of norepinephrine in the 
enalapril group may have interfered with mitochondrial res-
piration remains to be elucidated (29). Systemic and renal 
oxygen consumption were similar in groups with and with-
out enalapril. Theoretically, increased fractional excretion of 
sodium in enalapril-treated animals should have resulted in 
lower renal oxygen demands because sodium reabsorption 
is a major determinant of kidney oxygen consumption (30). 
However, mismatch between renal oxygen consumption and 
oxygen used for active sodium reabsorption, which accounts 
for 80% of renal oxygen consumption, has been reported (31). 
It is also possible that inflammation may have increased renal 
basal oxygen consumption.
Unexpectedly, animals treated with enalapril received a sig-
nificantly larger average hourly amount of fentanyl. This group 
was studied after the randomized norepinephrine and angio-
tensin II groups; slight genetic differences in opioid pharma-
cokinetics between the groups can therefore not be excluded. 
Furthermore, enalapril has been shown to alter cytochrome 
P450 activity (32). Alternatively or additionally, the low 
TABLE 3. Inflammatory Markers and Hematology
Variables Group Baseline
End of the 
 Observation 
Period Enda pb
Interleukin-6 (pg/mL) NE 14 (7–21) 521 (391–1,059) 85 (71–138) 0.008c
AT-II 18 (14–39) 486 (255–721) 104 (95–142) 0.008d
E 17 (17–27) 480 (284–624) 72 (57–217) 0.039e
Tumor necrosis factor-α (pg/mL) NE 76 (65–88) 194 (176–310) 110 (85–130) 0.008c
AT-II 86 (70–94) 198 (168–290) 124 (103–151) 0.016d
E 94 (72–118) 209 (176–277) 154 (110–183) 0.055e
Hemoglobin (g/dL) NE 9.1 (9.0–9.8) 14.3 (14.1–14.9) 9.5 (9.1–9.8) 0.008c
AT-II 8.8 (8.5–9.1) 13.7 (12.8–14.3) 8.7 (7.7–9.1) 0.008d
E 9.6 (9.1–9.9) 14.5 (13.5–14.6) 9.6 (9.3–10.9) 0.008e
Platelet (×109/L) NE 307 (261–356) 164 (122–183) 111 (99–132) 0.008c
AT-II 290 (217–356) 182 (124–155) 94 (65–149) 0.008d
E 371 (266–428) 247 (189–321) 139 (129–173) 0.008e
WBC count (×109/L) NE 20.8 (15.5–22.7) 13.6 (12.0–19.5) 21.1 (17.9–34.9) 0.008c
AT-II 19.0 (15.4–22.0) 10.1 (8.4–11.7) 23.8 (19.8–25.6) 0.008d
E 18.8 (17.8–21.2) 13.4 (10.8–15.9) 15.4 (13.0–18.6) 0.148e
Bands (%) NE 2.5 (0.8–6.0) 58.0 (47.3–65.5) 34.5 (25.5–47.3) 0.148c
AT-II 5.5 (2.5–8.5) 54.5 (46.3–65.8) 26.5 (22.0–60.8) 0.148d
E 1.0 (0.5–2.8) 58.3 (54.5–61.3) 22.8 (14.8–31.8) 0.008e
Metamyelocytes (%) NE 0.0 (0.0–0.0) 9.5 (5.5–11.5) 0.3 (0.0–4.0) 0.008c
AT-II 0.0 (0.0–0.0) 7.8 (6.0–12.5) 1.0 (0.3–4.3) 0.008d
E 0.0 (0.0–0.0) 5.8 (3.3–8.0) 0.5 (0.0–3.0) 0.008e
NE	=	norepinephrine		group,	AT-II	=	angiotensin	II	group,	E	=	enalapril	+	norepinephrine	group.
aEnd	of	the	experiment	(at	48	hr	of	resuscitation	or	before	death	if	earlier).
bTime	effect	with	Wilcoxon	signed	rank	test	including	end	of	the	observation	period	and	end	of	the	experiment	for	cNE,	dAT-II,	and	eE.
Values	are	medians	with	interquartile	ranges.
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cerebral perfusion pressure in the enalapril group and/or the 
high norepinephrine doses these animals received may have 
interfered with their reaction to painful stimuli.
All septic animals in our study needed glucose administra-
tion to maintain normal blood glucose concentrations, a fea-
ture characteristic to this porcine sepsis model. LPS infusion 
has been associated with reduced circulating glucose, insu-
lin, and insulin-like growth factor-1 in pigs (33). This may 
be related to physiologically reduced leptin concentrations, a 
potent regulator of food intake and metabolism. Animals pre-
treated with enalapril required a significantly smaller amount 
of glucose infusion compared with the norepinephrine group. 
We can only speculate that this was related to an increased 
endogenous glucose production rate as a consequence of the 
administration of more than three times higher norepineph-
rine doses in this group (34, 35).
As always, the fluid management in the present study can 
be questioned. We used an approach adopted from the sep-
sis guidelines (2), with regular clinical assessment of the ani-
mals including hemodynamics, tissue perfusion variables and 
diuresis, and added fluid bolus only as long as cardiac output 
increased. We believe that increased filling pressures and car-
diac output, maintained diuresis, and normal serum lactate 
concentrations at study end indicate that fluid management 
was adequate. Finally, the results from the enalapril group 
should be interpreted with caution since this group was not 
Figure 4. Isolated kidney mitochondrial respiration of complex I (a), complex II (b), and complex IV (c), respectively. NE = norepinephrine group,  
AT-II = angiotensin II group, E = enalapril + norepinephrine group. State 3 and 4 oxygen consumption is expressed as pmol/s/mg protein. State 3: 
active respiration after addition of adenosine diphosphate (ADP). State 4: respiration after consumption of ADP. RCR: respiratory control ratio (oxygen 
consumption of state 3/state 4). Horizontal lines represent median values. Filled circles represent animals that died early. p values: Mann-Whitney U test 
comparing (A) AT-II versus NE and (B) E versus NE.
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randomized. Further limitations are the relatively small group 
sizes and multiple testing with the risk of spurious false-posi-
tive findings.
CONCLUSIONS
In conclusion, we demonstrate that exogenous angiotensin II 
infusion was as efficient as norepinephrine to maintain arte-
rial blood pressure and cardiac output. Exogenous angioten-
sin II did not increase the prevalence of AKI or deteriorate 
mitochondrial respiration. In the context of our resuscitation 
protocol, arterial blood pressure goals could not be achieved 
when angiotensin-converting enzyme was inhibited before 
and during sepsis. Creatinine concentrations increased despite 
maintained renal blood flow and urinary output, and renal 
mitochondrial respiration efficiency was increased with enala-
pril treatment. The robustness of these findings and the long-
term effects of interference with the renin-angiotensin system 
on renal function and mitochondrial respiration in sepsis 
should be further evaluated.
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